Biogen Inc (BIIB) : Paloma Partners Management Co reduced its stake in Biogen Inc by 1.92% during the most recent quarter end. The investment management company now holds a total of 143,246 shares of Biogen Inc which is valued at $44,970,649 after selling 2,804 shares in Biogen Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Biogen Inc makes up approximately 1.73% of Paloma Partners Management Co’s portfolio.
Other Hedge Funds, Including , Snow Capital Management Lp boosted its stake in BIIB in the latest quarter, The investment management firm added 119,760 additional shares and now holds a total of 211,561 shares of Biogen Inc which is valued at $66,417,460. Biogen Inc makes up approx 2.93% of Snow Capital Management Lp’s portfolio.Cambridge Investment Research Advisors boosted its stake in BIIB in the latest quarter, The investment management firm added 404 additional shares and now holds a total of 5,356 shares of Biogen Inc which is valued at $1,692,282. Biogen Inc makes up approx 0.03% of Cambridge Investment Research Advisors’s portfolio.Montag Caldwell reduced its stake in BIIB by selling 178 shares or 13.93% in the most recent quarter. The Hedge Fund company now holds 1,100 shares of BIIB which is valued at $318,923. Biogen Inc makes up approx 0.01% of Montag Caldwell’s portfolio.Meeder Asset Management Inc boosted its stake in BIIB in the latest quarter, The investment management firm added 619 additional shares and now holds a total of 6,433 shares of Biogen Inc which is valued at $1,851,289. Biogen Inc makes up approx 0.17% of Meeder Asset Management Inc’s portfolio.
Biogen Inc opened for trading at $307.96 and hit $309.25 on the upside on Thursday, eventually ending the session at $306.03, with a gain of 0.13% or 0.4 points. The heightened volatility saw the trading volume jump to 10,68,034 shares. Company has a market cap of $67,058 M.
On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Downgraded by Jefferies to ” Hold” on Sep 6, 2016. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.